FAM133B

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FAM133B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM133B data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAM133B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM133B expression acts as an unfavorable survival marker.

HNSC and COAD are the cancer types where FAM133B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCOSMedianAll0.0130.768<.00148view →
COADOSMedianIII,IV0.2080.791.0089view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM133B–HNSC (OS)

Kaplan–Meier survival curve for FAM133B mutant vs wild-type samples in HNSC.

Open the HNSC breakdown →

Exploration